ArticleOncotarget2015
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 70 citations in OpenAlex.
- Advances in immune microenvironment profiling during multiple myeloma progression and therapy.International journal of hematology · 2026Review
- Review
- Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications.Frontiers in immunology · 2026Review
- Mechanistic Insights and Advances of Bispecific T Cell Engaging Antibodies Therapy in Multiple Myeloma.Medicina (Kaunas, Lithuania) · 2025Review
- Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model.Journal of medicinal chemistry · 2025Article
- A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages.Journal of hematology & oncology · 2024Article
- The Impact of Panobinostat on Cell Death in Combination with S63845 in Multiple Myeloma Cells.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Article
- Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.Biomarker research · 2023Review
- Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.Journal for immunotherapy of cancer · 2023Article
- Myeloid-derived suppressor cells are associated with impaired Th1 and Th17 responses and severe pulmonary paracoccidioidomycosis which is reversed by anti-Gr1 therapy.Frontiers in immunology · 2023Article
- Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.Frontiers in cell and developmental biology · 2023Review
- Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.Current oncology (Toronto, Ont.) · 2022Review
- Review
- Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin.Experimental hematology & oncology · 2022Review
- Tumor-associated macrophages in multiple myeloma: advances in biology and therapy.Journal for immunotherapy of cancer · 2022Review
- Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.International journal of molecular sciences · 2022Review
- The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.Frontiers in immunology · 2022Review
- The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.Molecular cancer therapeutics · 2022Article
- The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells.Frontiers in immunology · 2022Review
- Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid-derived suppressor cells (MDSC) are contributing to an immunosuppressive environment by their ability to inhibit T cell activity and thereby promoting cancer progression. An important feature of the incurable plasma cell malignancy Multiple Myeloma (MM) is immune dysfunction. MDSC were previously identified to be present and active in MM patients, however little is known about the MDSC-inducing and -activating capacity of MM cells. In this study we investigated the effects of the tumor microenvironment on MDSC survival. During MM progression in the 5TMM mouse model, accumulation of MDSC in the bone marrow was observed in early stages of disease development, while circulating myeloid cells were increased at later stages of disease. Interestingly, in vivo MDSC targeting by anti-GR1 antibodies and 5-Fluorouracil resulted in a significant reduced tumor load in 5TMM-diseased mice. In vitro generation of MDSC was demonstrated by increased T cell immunosuppressive capacity and MDSC survival was observed in the presence of MM-conditioned medium. Finally, increased Mcl-1 expression was identified as underlying mechanism for MDSC survival. In conclusion, our data demonstrate that soluble factors from MM cells are able to generate MDSC through Mcl-1 upregulation and this cell population can be considered as a possible target in MM disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.